SavedAdd your journal

Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 2

The Effects of Serous Macular Detachment on Treatment of Patients with Macular Edema Secondary to Central Retinal Vein Occlusion

Seröz Maküla Dekolmanının Santral Retinal Ven Tıkanıklığına Sekonder Gelişen Maküla Ödemi Tedavisine Etkisi

Akın ÇAKIR
Burak ERDEN
Selim BÖLÜKBAŞI
Alper Halil BAYAT
Mustafa Nuri ELÇİOĞLU
Pages
181–185
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SMD has good impact on visual gain in patients with CRVO.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effect of serous macular detachment (SMD) on anti-VEGF treatment in patients with macular edema (ME) secondaryto central retinal vein occlusion (CRVO)Materials and Methods: 46 eyes of 46 patients with ME due to CRVO were reviewed retrospectively.
📊
Key Findings & Data:At baseline and after every injection bestcorrected visual acuity (BCVA), central macular thickness (CMT), anatomical fi ndings were noted from optical coherence tomography (OCT)images and patients’ fi les.Results: 19 eyes in SMD and 27 eyes in non-SMD groups were studied.
💡
Conclusion & Impact:SMD has good impact on visual gain in patients with CRVO.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effect of serous macular detachment (SMD) on anti-VEGF treatment in patients with macular edema (ME) secondaryto central retinal vein occlusion (CRVO)Materials and Methods: 46 eyes of 46 patients with ME due to CRVO were reviewed retrospectively. The patients were divided into twogroups according to presence of the subretinal fl uid in optical coherence tomography (OCT): SMD and non-SMD. Both groups were treatedwith three monthly anti-VEGF (afl ibercept or ranibizumab) injections followed-up in PRN regimen. At baseline and after every injection bestcorrected visual acuity (BCVA), central macular thickness (CMT), anatomical fi ndings were noted from optical coherence tomography (OCT)images and patients’ fi les.Results: 19 eyes in SMD and 27 eyes in non-SMD groups were studied. The groups were similar in terms of baseline characteristics (p>0.05).Both groups had improvement in BCVA and decrease in CMT during treatment period (p0.05).Conclusion: The patients with SMD had higher anatomical gain and BCVA than patients with non-SMD during the fi rst months of the antiVEGF treatment. SMD has good impact on visual gain in patients with CRVO.

Özet

Amaç: Seröz maküla dekolmanının (SMD) santral retinal ven tıkınalıklığına (SRVT) sekonder gelişen maküla ödemli hastaların anti-VEGF tedavisine olan etkisini araştırmak Gereç ve yöntem: SRVT’ye seconder gelişen maküla ödemli 46 hastanın 46 gözü geriye dönük olarak incelendi. Hastalar optic koherans tomografi (OKT) görüntülerinde subretinal sıvı olup olmamasuna göre iki gruba ayrıldılar: seröz maküla dekolmaı olan grup (SMD) ve SMD olmayan grup. Her iki grup da 3 aylık ardışık anti-VEGF (ranibizumab veya afl ibercept) tedavi sonrası PRN rejimiyle takip edildiler. Başlangıçta ve her enjeksiyon sonrası hastaların en iyi düzeltilmiş görme keskinlikleri (EİDGK), santral maküla kalınlıklar (SMK) ve anatomik bulguları hasta dosyalarından ve OKT görüntülerinden not edildi. Bulgular: SMD olan grupta 17, SMD olmayan grupta 26 hasta vardı. Gruplar demografi k yapı açısından benzerdi (p>0.05). Tedavi süresince her iki grupta da görme ve anatomik kazanım sağlanmıştır (p0.05) Sonuç: SMD olan hastalar anti-VEGF tedavinin ilk aylarında SMD olmayan hastalara göre daha iyi görme kazanımı sağlamıştır. SMD, SRVT’li hastalarda görme kazanımı üzerine olumlu etki sağlamıştır.

🔖

Cite This Article

ÇAKIR, A., ERDEN, B., BÖLÜKBAŞI, S., BAYAT, A. H., ELÇİOĞLU, M. N. (2022). The Effects of Serous Macular Detachment on Treatment of Patients with Macular Edema Secondary to Central Retinal Vein Occlusion. Retina-Vitreus, Cilt: 28 - Sayı: 2, 181–185. https://ajindex.com/articles/589116

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Klein R, Moss SE, Meuer SM, Klein BE. (2008) The 15-year cumulative incidence of retinal vein occlusion. The Beaver Dam eye study. Arch Ophthalmol. 126:513-8
  2. Ehlers JP, Fekrat S. (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 56:281-99
  3. Hayreh SS, Podhajsky PA, Zimmerman MB. (2011) Natural history of visual outcome in central retinal vein occlusion. Ophthalmology.118(119-33):e1-2
  4. Noma H, Mimura T, Masahara H, Shimada K (2014) Pentraxin 3 and other infl ammatory factors in central retinal vein occlusion and macular edema. Retina 34:352-9
  5. Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 38:904-10
  6. Deobhakta A, Chang LK (2013) Infl ammation in retinal vein occlusion. Int J Infl am 2013:438412
  7. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87-93
  8. Jung SH, Kim KA, Sohn SW, Yang SJ (2014) Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci 55:2290-6
  9. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N,Murahashi WY, Rubio RG (2011) Sustained benefi ts from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041-9
  10. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802-9
  11. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusiontreated with ranibizumab: the RETAIN study. Ophthalmology 121:209-19
  12. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, MaY, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal afl ibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121:1414-20
  13. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, SchmidtErfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, GALILEO Study Group (2014) Intravitreal afl ibercept inj